BioDrugs

, Volume 16, Issue 2, pp 105–109 | Cite as

Peginterferon-α-2a (40kD) and Ribavirin in Patients with Chronic Hepatitis C

A Phase II Open-Label Study
  • Mark Sulkowski
  • Robert Reindollar
  • David L. Thomas
  • Sherilyn Brinkley-Laughton
  • Martha Hudson
  • Jian Yu
Original Research Article

Abstract

Background and aims: Addition of a 40kD polyethylene glycol moiety to interferon-α-2a [peginterferon-α-2a (40kD)] improves pharmacokinetic properties over those of standard interferon. We conducted a phase II study to assess the safety and initial efficacy of peginterferon-α-2a (40kD) plus ribavirin combination therapy in patients with chronic hepatitis C (CHC).

Methods: Twenty patients received open-label 180μg peginterferon-α-2a (40kD) subcutaneously once weekly and oral ribavirin 1000 or 1200mg daily for patients weighing <75 or ≥75kg, respectively, for a period of 24 weeks. Patients with hepatitis C virus (HCV) genotype 1 and a virological response at week 24 received study drugs for an additional 24 weeks.

Results: A sustained virological response, defined as undetectable HCV RNA 24 (i.e. <100 copies/ml) weeks after completing the therapy, was achieved in 50% of patients in an intent-to-treat analysis (6/16 genotype 1 and 4/4 genotype non-1). Adverse events were similar to those reported with unmodified interferon plus ribavirin combination therapy. Anaemia led to ribavirin dose reduction in five patients. Neutropenia led to dose reduction in three patients treated with peginterferon-α-2a (40kD).

Conclusions: The addition of ribavirin to a once-weekly peginterferon-α-2a (40kD) regimen should be investigated in larger clinical trials.

References

  1. 1.
    Carithers Jr RL, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 1997; 26Suppl. 1: 83S–8SPubMedCrossRefGoogle Scholar
  2. 2.
    Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778–89PubMedCrossRefGoogle Scholar
  3. 3.
    Farrell GC. Therapy of hepatitis C: interferon alfa-n1 trials. Hepatology 1997; 26Suppl. 1: 96S–100SPubMedCrossRefGoogle Scholar
  4. 4.
    McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485–92PubMedCrossRefGoogle Scholar
  5. 5.
    Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426–32PubMedCrossRefGoogle Scholar
  6. 6.
    Wills RJ, Dennis S, Spiegel HE, et al. Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection. Clin Pharmacol Ther 1984; 35: 722–7PubMedCrossRefGoogle Scholar
  7. 7.
    Xu Z-X, Hoffman J, Patel I, et al. Single-dose safety/tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon α-2a (IFN α-2a) to healthy subjects [abstract]. Hepatology 1998; 28: 702CrossRefGoogle Scholar
  8. 8.
    Algranati NE, Sy S, Modi M. A branched methoxy 40 kDa polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of peginterferon α-2a (PEG[40kDa] IFN αa-a) and may explain its enhanced efficacy in chronic hepatitis C (CHC) [abstract]. Hepatology 1999; 30: 190AGoogle Scholar
  9. 9.
    Pockros PJ, Heathcote EJ, Shiffman ML, et al. Efficacy of pegylated (40kDa) interferon alfa-2α (PEGASYS®) in randomized trials of patients with chronic hepatitis C, with and without cirrhosis: correlation of virological and histological responses with baseline liver histology and genotype [abstract]. Hepatology 2000; 32: 442ACrossRefGoogle Scholar
  10. 10.
    Reddy R, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40kDa) interferon α-2a compared with interferon α-2a in non-cirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 433–8PubMedCrossRefGoogle Scholar
  11. 11.
    Heathcote, EJ, Shiffman ML, et al. Peginterferon α-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673–80PubMedCrossRefGoogle Scholar
  12. 12.
    Zeuzem S, Feinman SV, Rasenack EJ, et al. Induction regimen of interferon α-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666–72PubMedCrossRefGoogle Scholar
  13. 13.
    Brouwer JT, Hansen BE, Niesters HGM, et al. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. J Hepatol 1999; 30: 192–8PubMedCrossRefGoogle Scholar
  14. 14.
    Schiff ER, De Medina M, Kahn RS. New perspectives in the diagnosis of hepatitis C. Semin Liver Dis 1999; 19Suppl. 1: 3–15PubMedGoogle Scholar
  15. 15.
    Chemello L, Cavalletto L, Bernardinello E, et al. The effect of interferon alfa and ribavirin combination therapy in naïve patients with chronic hepatitis C. J Hepatol 1995; 23: 8–12PubMedCrossRefGoogle Scholar
  16. 16.
    Rebetol [package insert]. Kenilworth (NJ): Schering-Plough; 1998Google Scholar
  17. 17.
    Haria M, Benfield P. Interferon-α-2a: a review of its pharmacological properties and therapeutic use in the management of viral hepatitis. Drugs 1995; 50(5): 873–96PubMedCrossRefGoogle Scholar
  18. 18.
    Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–65PubMedCrossRefGoogle Scholar
  19. 19.
    Fried MW, Shiffman ML, Reddy KR, et al. Pegylated (40 kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin: efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study. Gastroenterology 2001; 1205 Suppl. 1: A55Google Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • Mark Sulkowski
    • 1
  • Robert Reindollar
    • 2
  • David L. Thomas
    • 1
  • Sherilyn Brinkley-Laughton
    • 1
  • Martha Hudson
    • 2
  • Jian Yu
    • 3
  1. 1.The Johns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Carolinas Center for Liver Disease, North CarolinaCharlotteUSA
  3. 3.F. Hoffmann-La Roche Inc.NutleyUSA

Personalised recommendations